Naloxone training and availability in the US commercial fishing industry.  Bellantoni, JM, Bulzacchelli, MT, Orchard, D, Sulman, HB, Bartlett, JJ, Dzugan, J.  Am J Ind Med. 2023; 1- 5. doi:10…

USA. New overdose antidote approved, but concerns raised about cost, side effects The Food and Drug Administration on Monday approved a nasal-spray medication touted as another option to reverse overdoses caused by synthetic opioids, including…

USA. Indivior Announces U.S. Food and Drug Administration Approval of OPVEE® (nalmefene) Nasal Spray, An Opioid Overdose Rescue Medicine for Natural and Synthetic Opioids Like Fentanyl Richmond, Va., May 22, 2023 – Indivior PLC (LSE: INDV) tod…

Zwischenstand des Bundesmodellprojektes NALtrain zum Thema Take-Home Naloxon Im Rahmen des akzept-Kongresses in Berlin (04.05-05.05.) wurden die Zwischenergebnisse des Bundemodellprojektes NALtrain vorgestellt. Das Projekt fördert die Durchführung…

Effects of Gabapentinoids on Heroin-Induced Ventilatory Depression and Reversal by Naloxone.  Flynn SM, France CP.  ACS Pharmacol Transl Sci. 2023 Mar 6;6(4):519-525. doi: 10.1021/acsptsci.2c00230. PMID: 37082751; PMCID: PMC10111619. Ab…

Sweden's first Take-Home Naloxone program: participant characteristics, dose endpoints and predictors for overdose reversals.  Holmén E, Warnqvist A, Kåberg M.  Subst Abuse Treat Prev Policy. 2023 Apr 22;18(1):24. doi: 10.1186/s13011-023…